NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• The NY-ESO-1 gene is a tumor antigen expressed in various human cancers.
• NY-ESO-1 encodes peptides recognized by CD8+ cytotoxic T lymphocytes (CTLs) in an HLA-A2-restricted manner.
• The potential for NY-ESO-1 to be recognized by CD4+ T cells remains less explored.

Purpose of the Study:

• To identify and characterize novel NY-ESO-1-derived peptides presented by HLA-DRB1*0401.
• To investigate the immunogenicity and T-cell response to these novel peptides.
• To evaluate the potential of these peptides in cancer immunotherapy.

Main Methods:

• Peptide identification and synthesis.
• In vitro induction of CD4+ T cells from healthy donors and melanoma patients.
• Assays for T-cell proliferation, cytokine production (IFN-gamma), and cytotoxicity.
• Analysis of T-cell recognition of peptide-pulsed cells and tumor cell lines.

Main Results:

• The NY-ESO-1 gene encodes two overlapping, non-cross-reactive peptides presented by HLA-DRB1*0401.
• The peptide NY-ESO-1(119-143) induced specific CD4+ T cells in vitro.
• Induced CD4+ T cells produced IFN-gamma and lysed target cells presenting the NY-ESO-1(119-143) peptide.
• The NY-ESO-1(119-143) peptide contains two distinct core epitopes recognized by non-cross-reactive CD4+ T-cell clones.

Conclusions:

• The novel DR4-restricted tumor peptide NY-ESO-1(119-143) is recognized by CD4+ T cells.
• This peptide and its sub-epitopes can elicit specific CD4+ T-cell responses.
• NY-ESO-1(119-143) and its sub-epitopes are potential candidates for cancer immunotherapeutic strategies targeting NY-ESO-1-expressing tumors.